8 Analysts Have This to Say About Mirati Therapeutics
Portfolio Pulse from Benzinga Insights
Eight analysts have provided ratings for Mirati Therapeutics (NASDAQ:MRTX) in the last quarter, with four being somewhat bullish and four indifferent. The average price target is $56.38, compared to the current price of $35.625, implying an upside. However, this average has decreased by 7.57% from the previous average price target of $61.00.
July 14, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mixed analyst ratings for Mirati Therapeutics with an average price target of $56.38, implying an upside.
The mixed analyst ratings indicate uncertainty about the company's future performance. However, the average price target is significantly higher than the current price, suggesting potential upside. This could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100